Bacterial vaginosis in the first trimester of pregnancy: microbiological and immunological indicators in the evaluation of therapy efficiency
Objective. To investigate defensin production in pregnant women with bacterial vaginosis.Dobrokhotova Yu.E., Borovkova E.I., Hertek S.E., Koroleva V.I.
Subjects and methods. Seventy pregnant women with bacterial vaginosis (according to the Amsel criteria) were examined and treated. The investigators formed a study group of 40 patients receiving Tergynan for 10 days and a control one of 30 patients taking Hexicon for 10 days; the patients’ median age was 29.3 years. They performed a culture study of vaginal microbiocenosis, an immunological study of the expression of defensin genes by real-time reverse transcription PCR, and statistical processing.
Results. The course of the first and second trimesters was not different in the groups. The control group of patients in the third trimester more often developed a threat of preterm labor and urinary tract infection. Delivery at term occurred in 97.5% of the pregnant women in the study group; preterm labor was seen in 10% in the control group. Recurrent bacterial vaginosis developed in 10 and 43.3% in the study and control groups, respectively. In the study group, the normocenosis persisted at day 30 after treatment and at weeks 34–36.
Conclusion. The expression of defensin was substantially increased in the presence of bacterial vaginosis. Following 10 days, the level of defensin in the study group decreased 1.7-fold and persisted at day 30 and at weeks 34–36; that in the control group declined 1.4-fold; at day 30, the expression of the factor returned to the baseline values and remained until the end of pregnancy.
Keywords
bacterial vaginosis
pregnancy
preterm labor
mucosal immunity
defensin
Tergynan
chlorhexidine
References
- Schoeman J., Steyn P.S., Odendaal H.J., Grové D. Bacterial vaginosis diagnosed at the first antenatal visit better predicts preterm labour than diagnosis later in pregnancy. J. Obstet. Gynaecol. 2005; 25(8): 751-3. https://dx.doi.org/10.1080/01443610500314660.
- Klebanoff M.A., Hillier S.L., Nugent R.P., MacPherson C.A., Hauth J.C., Carey J.C. et al. Is bacterial vaginosis a stronger risk factor for preterm birth when it is diagnosed earlier in gestation? Am. J. Obstet. Gynecol. 2005; 192(2): 470-7. https://dx.doi.org/10.1016/j.ajog.2004.07.017.
- UK National guideline for the management of bacterial vaginosis. 2012. Available at: https://www.bashh.org/documents/4413.pdf Accessed on June 15, 2017.
- Leitich H., Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. Best Pract. Res. Clin. Obstet. Gynaecol. 2007; 21(3): 375-90. https://dx.doi.org/10.1016/j.bpobgyn.2006.12.005.
- Bohbot J.M., Vicaut E., Fagnen D., Brauman M. Treatment of bacterial vaginosis: a multicenter, double-blind, double-dummy, randomised phase III study comparing secnidazole and metronidazole. Infect. Dis. Obstet. Gynecol. 2010; 2010: 705692. https://dx.doi.org/10.1155/2010/705692.
- Thinkhamrop J., Hofmeyr G.J., Adetoro O., Lumbiganon P., Ota E. Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity. Cochrane Database Syst. Rev. 2015; (6): CD002250.https://dx.doi.org/10.1002/14651858.CD002250.pub3.
- Klebanoff M.A., Hauth J.C., MacPherson C.A., Carey J.C., Heine RP., Wapner R.J. et al. Time course of the regression of asymptomatic bacterial vaginosis in pregnancy with and without treatment. Am. J. Obstet. Gynecol. 2004; 190(2): 363-70. https://dx.doi.org/10.1016/j.ajog.2003.08.020.
- Hoffmann J., Akira S. Innate immunity. Curr. Opin. Immunol. 2013; 25(1): 1-3.https://dx.doi.org/10.1016/j.coi.2013.01.008.
- Jones J.D., Vance R.E., Dangl J.L. Intracellular innate immune surveillance devices in plants and animals. Science. 2016; 354(6316): aaf6395. https://dx.doi.org/10.1126/science.aaf6395.
- Medzhitov R. Pattern recognition theory and the launch of modern innate immunity. J. Immunol. 2013; 191(9): 4473-4. https://dx.doi.org/10.4049/jimmunol.1302427.
- Doss M., White M.R., Tecle T., Hartshorn K.L. Human defensins and LL-37 in mucosal immunity. J. Leukoc. Biol. 2010; 87(1): 79-92. https://dx.doi.org/10.1189/jlb.0609382.
- Steinstraesser L., Kraneburg U., Jacobsen F., Al-Benna S. Host defense peptides and their antimicrobial-immunomodulatory duality. Immunobiology. 2011; 216(3): 322-33. https://dx.doi.org/10.1016/j.imbio.2010.07.003.
- Chu H., Pazgier M., Jung G., Nuccio S.P., Castillo P.A., de Jong M. et al. Human α-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets. Science. 2012; 337(6093): 477-81. https://dx.doi.org/10.1126/science.1218831.
- Torow N., Hornef M.W. The neonatal window of opportunity: setting the stage for life-long host-microbial interaction and immune homeostasis. J. Immunol. 2017; 198(2): 557-63. https://dx.doi.org/10.4049/jimmunol.1601253.
- Доброхотова Ю.Э., Боровкова Е.И., Зайдиева З.С., Степанянц И.В. Состояние врожденного иммунитета и микробиоты влагалища при бактериальном вагинозе у беременных в I триместре. Акушерство и гинекология. 2019; 9: 126-34. [Dobrokhotova Yu.E., Borovkova E.I., Zaydieva Z.S., Stepanyants I.V. The state of innate immunity and vaginal microbiota in bacterial vaginosis in pregnant women in the first trimester. Akusherstvo i Ginekologiya / Obstetrics and Gynecology). 22019; 9: 126-34. (in Russian)]. https://dx.doi.org/10.18565/aig.2019.9.126-134.
Received 16.05.2020
Accepted 25.05.2020
About the Authors
Yulia E. Dobrokhotova, MD, Professor, Head of Department of Obstetrics and Gynecology, Faculty of General Medicine, N.I. Pirogov Russian National Research Medical University, Moscow, Russia. Tel: +7 (495)722-6399. E-mail: pr.dobrohotova@mail.ru 1, Ostrovityanov st., Build. 9, Moscow, 117997, Russia.Ekaterina I. Borovkova, MD, Associate Professor, Professor of Therapeutical Faculty, Obstetrics and Gynecology Department N.I. Pirogov Russian National Research Medical University, Moscow, Russia. Tel:+7(903)785-5793. E-mail: Katyanikitina@mail.ru. 1, Ostrovityanov st., Build. 9, Moscow, 117997, Russia.
Snezhana E. Hertek, Clinical Resident, Department of Obstetrics and Gynecology, Faculty of General Medicine, N.I. Pirogov Russian National Research Medical University. Tel.: +7 (923)383-50-07. E-mail: cnejano4ka@mail.ru. ORCID: 0000-0002-2172-0803.
1, Ostrovityanov st., Build. 9, Moscow, 117997, Russia.
Valeria I. Koroleva, Clinical Resident, Department of Obstetrics and Gynecology, Faculty of General Medicine, N.I. Pirogov Russian National Research Medical University. ORCID: 0000-0003-0502-3802. 1, Ostrovityanov st., Build. 9, Moscow 117997, Russia.
For reference: Dobrokhotova Yu.E., Borovkova E.I., Hertek S.E., Koroleva V.I. Bacterial vaginosis in the first trimester of pregnancy: microbiological and immunological indicators in the evaluation of therapy efficiency.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2020; 6: 98-104 (in Russian).
https://dx.doi.org/10.18565/aig.2020.6.98-104
Similar Articles
